kantar Archives - Page 3 of 4 -

Exclusive live coverage from day three of the American Society of Clinical Oncology’s annual meeting in Chicago. •

ASCO 2019 day three

https://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-three/

ASCO 2019 and the future of oncology/ Video/ Views & Analysis/ Views and analysis

ASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trial

Mike Smith ASCO 2019, kantar, Oncology 0 Comment

Will Erleada take the lead in metastatic CSPC? New interim data at ASCO 2019 from the Phase 3

ASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trial

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-interim-data-phase-3-titan-trial/

ASCO 2019 Live coverage/ Oncology/ Views & Analysis/ Views and analysis

ASCO 2019 day two

mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment

Exclusive live coverage from day two of the American Society of Clinical Oncology’s annual meeting in Chicago. •

ASCO 2019 day two

https://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-two/

ASCO 2019 Live coverage/ Oncology/ Spotlight/ Views & Analysis/ Views and analysis

ASCO 2019 day one

mike.hammerton@pharmaphorum.com ASCO 2019, kantar, Oncology 0 Comment

Exclusive live coverage from day one of the American Society of Clinical Oncology’s annual meeting in Chicago. •

ASCO 2019 day one

https://pharmaphorum.com/spotlight/asco-2019-live-coverage/asco-2019-day-one/

ASCO 2019 and the future of oncology/ Oncology/ Views & Analysis/ Views and analysis

ASCO 2019 Preview – in partnership with Kantar

Mike Smith ASCO 2019, kantar, Oncology 0 Comment

ASCO’s 2019 conference is due to begin in just a few days’ time, highlighting the latest cutting edge

ASCO 2019 Preview – in partnership with Kantar

https://pharmaphorum.com/views-analysis-oncology/asco-2019-preview-partnership-kantar/

Oncology/ Views & Analysis/ Views and analysis

ASCO 2019 and the future of oncology

Mike Smith ASCO 2019, kantar, Oncology 0 Comment

The future of oncology is to be showcased at ASCO 2019 when the world’s leading cancer event returns

ASCO 2019 and the future of oncology

https://pharmaphorum.com/views-and-analysis/spotlight-asco-2019-future-oncology/

Patients/ Views & Analysis/ Views and analysis

Affordability is blocking worldwide access to medication

Amanda Barrell access to medication, Global Health and Wellness Report, kantar, prescriptions 0 Comment

Our growing understanding of human biology is accelerating medical science at an unprecedented rate – but more needs

Affordability is blocking worldwide access to medication

https://pharmaphorum.com/views-analysis-patients/affordability-is-blocking-worldwide-access-to-medication/

Debates & Insight/ Debates & Insights/ Sales and Marketing/ Slider in whitepapers/ White Papers

Marketing science – brand innovation for pharma

Dominic Tyer brand innovation, kantar, marketing science, pharma marketing 0 Comment

Combining fields such as economics, statistics and operations research, marketing science has for some time operated under-the-radar as

Marketing science – brand innovation for pharma

https://pharmaphorum.com/debates-insight-sales-marketing/marketing-science-brand-innovation-for-pharma/

Cancer/ ESMO2016/ R&D

Cancer market commentary: Roche’s Tecentriq muscles into NSCLC

Andrew McConaghie BMS, breakthrough, cancer, docetaxel, ESMO, kantar, Keytruda, Merck, Opdivo, Roche, Tecentriq, trial 0 Comment

Roche’s PD-L1 drug has generated impressive data in second line lung cancer

Cancer market commentary: Roche’s Tecentriq muscles into NSCLC

https://pharmaphorum.com/esmo-2016/cancer-market-commentary-roches-tecentriq-muscles-nsclc/

Trending

kantar

Login